Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465347 | 0.75 | NOS1 (0.47) | HTTPTK2TGFBR1CYP3A4CYP2C8 | |
| SCHEMBL2598398 | 0.75 | NOS1 (0.47) | HTTPTK2TGFBR1CYP3A4CYP2C8 | |
| SCHEMBL3466097 | 0.75 | HTT (0.41) | HTTPTK2TGFBR1CYP3A4CYP2C8 | |
| SCHEMBL29514304 | 0.75 | NOS1 (0.47) | HTTPTK2TGFBR1CYP3A4CYP2C8 | |
| SCHEMBL2598373 | 0.75 | MAPKAPK2 (0.38) | HTTPTK2TGFBR1MAPKAPK2CYP3A4 | |
| SCHEMBL19152664 | 0.75 | HTT (0.45) | HTTPTK2MAPTTGFBR1CYP3A4 | |
| SCHEMBL23629273 | 0.72 | BTK (0.54) | PTK2CHEK1PIM1RETLRRK2 | |
| SCHEMBL18237978 | 0.71 | HTT (0.37) | HTTPTK2MAPTTGFBR1CYP3A4 | |
| SCHEMBL20874628 | 0.71 | KDM4E (0.46) | HTTPTK2MAPTTGFBR1RET | |
| SCHEMBL29951183 | 0.71 | HTT (0.41) | HTTPTK2MAPTTGFBR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | H. LUNDBECK A/S (DK) | 2023-04-25 | — | — | US | claimed |
| EP-3723808-B1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H LUNDBECK AS (DK) | 2021-10-20 | — | — | EP | claimed |
| EP-3723808-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H. Lundbeck A/S (DK) | 2020-10-21 | — | — | EP | claimed |
| EP-3723807-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H. Lundbeck A/S (DK) | 2020-10-21 | — | — | EP | claimed |
| WO-2019115567-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H. LUNDBECK A/S (DK) | 2019-06-20 | — | — | WO | claimed |
| WO-2019115566-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H. LUNDBECK A/S (DK) | 2019-06-20 | — | — | WO | claimed |
| EP-3478681-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | H. Lundbeck A/S (DK) | 2019-05-08 | — | — | EP | claimed |
| WO-2018007249-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-01-11 | — | — | WO | claimed |
| WO-2011146287-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-24 | — | — | WO | claimed |
| WO-2026088205-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | INTONATION RESEARCH LABORATORIES PRIVATE LIMITED. (IN) | 2026-04-30 | — | — | WO | disclosed |
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | H. LUNDBECK A/S (DK) | 2023-12-26 | — | — | US | disclosed |
| CN-111556871-B | 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors | H.隆德贝克有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | H. LUNDBECK A/S (DK) | 2023-04-25 | — | — | US | disclosed |
| US-11535611-B2 | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-12-27 | — | — | US | disclosed |
| US-20190105302-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2019-04-11 | — | — | US | disclosed |
| US-10034861-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2018-07-31 | — | — | US | disclosed |
| WO-2018007249-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-01-11 | — | — | WO | disclosed |
| US-20180000786-A1 | 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2018-01-04 | — | — | US | disclosed |
| WO-2011146287-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-24 | — | — | WO | disclosed |
| US-4716160-A | Certain 7-amino-pyrazolo[4,3-b]pyridines useful in treating inflammatory and allergic disorders | BEECHAM GROUP P.L.C. (GB) | 1987-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10034861-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE3A, PDE5A, PDE12 | NCF1 2805/4885PTPN11 1391/4885HTT 1321/4885 |
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | PDE3B, PDE1B, PDE12 | NCF1 2445/4885PTPN11 2111/4885HTT 551/4885 |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | PDE1B, PDE3B, PDE1A | NCF1 3266/4885PTPN11 1760/4885HTT 2881/4885 |
| US-20180000786-A1 | 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors | PDE3A, PDE5A, PDE12 | NCF1 2805/4885PTPN11 1391/4885HTT 1321/4885 |
| US-11535611-B2 | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors | PDE5A, PDE12, PDE3A | NCF1 2765/4885PTPN11 1329/4885HTT 1703/4885 |
| US-20190105302-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | PDE3A, PDE5A, PDE12 | NCF1 2805/4885PTPN11 1391/4885HTT 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.